|

Linperlisib Clinical Trials

1 actively recruiting trial

Also known as: YY-20394

Pipeline

Phase 1/2: 1

Top Sponsors

  • Beijing Tongren Hospital1

Indications

  • Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type1
  • T-lymphoblastic Lymphoma1
  • Cancer1

Other1 trial

Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.